Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
Want to see ACRS full AI Analyst Report?
Top Page
Aclaris Therapeutics
(NASDAQ:ACRS)
Select Model
Select Model
Rating:51Neutral
Price Target:
$4.50
▲(5.88% Upside)
Action:ReiteratedDate:04/28/26
The score is held down primarily by weak financial performance (sharp revenue decline, large ongoing losses, and significant cash burn). Offsetting factors include improving technical trend/momentum and supportive corporate developments (positive early clinical data and added funding, albeit dilutive), while valuation is constrained by negative earnings and no dividend.
Positive Factors
Best-in-class PK for ATI-052
Aclaris’s ATI-052 demonstrated ~45-day half-life and sustained PD through weeks 12–20 in Phase 1a. Durable PK/PD supporting up-to-q3-month dosing is a structural competitive advantage: lowers dosing frequency, improves adherence and commercial differentiation versus shorter-acting biologics, aiding long-term market positioning.
Negative Factors
High cash burn
Persistent ~-$47M TTM operating and free cash flow creates a structural funding requirement. Ongoing high burn relative to limited revenue forces repeated capital raises or partnerships, risks program delays if financing conditions tighten, and steadily depletes shareholder value absent clinical or commercial inflection points.
Read all positive and negative factors
Positive Factors
Negative Factors
Best-in-class PK for ATI-052
Aclaris’s ATI-052 demonstrated ~45-day half-life and sustained PD through weeks 12–20 in Phase 1a. Durable PK/PD supporting up-to-q3-month dosing is a structural competitive advantage: lowers dosing frequency, improves adherence and commercial differentiation versus shorter-acting biologics, aiding long-term market positioning.
Read all positive factors
Aclaris Therapeutics (ACRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$632.68M
Dividend YieldN/A
Average Volume (3M)1.11M
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth-58.20%
EPS Growth64.96%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.53
Shares Outstanding139,663,680
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue70.92
Enterprise Value/Gross Profit96.77
Enterprise Value/Ebitda-8.10
Forecast
1Y Price Target
$11.29Price Target Upside165.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$4.69M
Aclaris Therapeutics Business Overview & Revenue Model
Company Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therape...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Aclaris Therapeutics primarily seeks to generate value by developing drug candidates and, if successful, monetizing them through commercialization and/or business development transactions (such as lic...
Aclaris Therapeutics Earnings Call Summary
Earnings Call Date:May 07, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The earnings call highlights Aclaris' strong financial position and promising advancement of ATI-2138, despite some challenges in cash reserves and competitive landscape considerations. The company is making strategic moves in its drug development with a focus on efficiency and differentiation.Positive Updates
Strong Financial Position
Aclaris ended the first quarter with $161 million in cash, cash equivalents, and marketable securities, with no outstanding debt. This positions the company well financially for upcoming initiatives.
Negative Updates
Decreased Cash Reserves
Cash reserves decreased from $182 million at year-end to $161 million at the end of Q1, partly due to nonrecurring payments related to discontinued programs and severance.
Read all updates
Q1-2024 Updates
Positive
Negative
Strong Financial Position
Aclaris ended the first quarter with $161 million in cash, cash equivalents, and marketable securities, with no outstanding debt. This positions the company well financially for upcoming initiatives.
Read all positive updates
Company Guidance
During the Aclaris Therapeutics Q1 2024 earnings call, several key metrics and strategic updates were provided. The company ended the first quarter with cash, cash equivalents, and marketable securities totaling $161 million, down from $182 million at the end of the previous year. Approximately $14 million of the expenditures in the first quarter were related to nonrecurring payments. Aclaris has decided to advance ATI-2138, their oral small molecule ITK JAK3 inhibitor, into a Phase II proof-of-concept study targeting atopic dermatitis. The study is designed as an open-label trial involving 15 patients over 12 weeks, with a focus on safety, pharmacokinetics (PK), and early efficacy signals. Joseph Monahan highlighted that ATI-2138 is 44.4 times more potent than ritlecitinib in blocking ITK-dependent cytokine production and 5.4 times more potent in JAK3-dependent readouts. Financially, Aclaris is committed to maintaining a strong balance sheet with ongoing cost containment initiatives and exploring business development opportunities to source nondilutive capital.Aclaris Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.83M | 18.72M | 31.25M | 29.75M | 6.76M |
| Gross Profit | 5.74M | 15.93M | 13.17M | 17.79M | 2.05M |
| EBITDA | -64.47M | -51.72M | -115.45M | -84.36M | -64.46M |
| Net Income | -64.92M | -132.06M | -88.48M | -86.91M | -90.86M |
Balance Sheet | |||||
| Total Assets | 160.46M | 220.33M | 197.41M | 254.60M | 251.21M |
| Cash, Cash Equivalents and Short-Term Investments | 90.75M | 113.59M | 119.11M | 217.57M | 191.41M |
| Total Debt | 2.12M | 0.00 | 426.00K | 684.00K | 693.00K |
| Total Liabilities | 57.38M | 64.77M | 40.23M | 56.98M | 53.87M |
| Stockholders Equity | 103.08M | 155.55M | 157.18M | 197.62M | 197.34M |
Cash Flow | |||||
| Free Cash Flow | -47.11M | -20.20M | -79.63M | -68.17M | -52.44M |
| Operating Cash Flow | -47.11M | -20.07M | -78.33M | -67.57M | -52.13M |
| Investing Cash Flow | 48.37M | -69.77M | 46.22M | 12.63M | -167.63M |
| Financing Cash Flow | -5.86M | 74.54M | 26.71M | 72.87M | 225.05M |
Aclaris Therapeutics Technical Analysis
Positive
4.25
Price Trends
3.55
Positive
3.34
Positive
2.63
Positive
Market Momentum
0.15
Negative
63.18
Neutral
71.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRS, the sentiment is Positive. The current price of 4.25 is above the 20-day moving average (MA) of 3.82, above the 50-day MA of 3.55, and above the 200-day MA of 2.63, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 63.18 is Neutral, neither overbought nor oversold. The STOCH value of 71.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRS.
Aclaris Therapeutics Risk Analysis
Aclaris Therapeutics disclosed 72 risk factors in its most recent earnings report. Aclaris Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aclaris Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $632.68M | -4.66 | -52.04% | ― | -58.20% | 64.96% | |
48 Neutral | $140.55M | -3.31 | -164.68% | ― | 99.17% | 56.27% | |
48 Neutral | $74.40M | -4.68 | -47.69% | ― | 5.19% | 32.03% | |
45 Neutral | $104.78M | -2.38 | 516.59% | ― | 19.80% | 47.35% | |
44 Neutral | $74.56M | -7.01 | -126.62% | ― | 19.65% | -10.83% | |
42 Neutral | $10.39M | -0.17 | -44.77% | ― | 8.19% | 56.09% |
* Healthcare Sector Average
ACRS
Aclaris Therapeutics
4.53
3.28
262.40%
NOTV
Inotiv
0.30
-1.71
-84.98%
MDXH
MDxHealth
2.04
0.33
19.30%
STIM
Neuronetics
2.02
-2.54
-55.70%
XGN
Exagen
3.10
-3.73
-54.61%
SERA
Sera Prognostics
1.90
-0.50
-20.83%
Aclaris Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Aclaris Reports Positive ATI-052 Phase 1a Trial Results
Positive
Apr 28, 2026
On April 28, 2026, Aclaris Therapeutics reported positive full top-line results from a first-in-human Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in healthy volunteers, highlighting a ...
Business Operations and StrategyPrivate Placements and Financing
Aclaris Therapeutics Raises $20 Million in Equity Financing
Positive
Mar 12, 2026
On March 10, 2026, Aclaris Therapeutics, Inc. raised $20 million in gross proceeds through the sale of 5.7 million shares of its common stock under an amended and restated sales agreement with Leerink Partners and Cantor Fitzgerald. The shares wer...
Private Placements and FinancingRegulatory Filings and Compliance
Aclaris Therapeutics Raises Capital via Institutional Stock Sale
Positive
Mar 10, 2026
From March 2 to March 9, 2026, Aclaris Therapeutics, Inc. sold 12.7 million shares of its common stock, raising gross proceeds of $39.8 million under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald Co. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.